EASL Clinical Practice Guidelines

References

[1]Paganelli, M., Stephenne, X., and Sokal, E.M. Chronic hepatitis B in children and adolescents. J Hepatol. 2012; 57: 885896
Abstract | Full Text | Full Text PDF | PubMed | Scopus (8)

[2]Chang, M., Hsu, H., Hsu, H., Ni, Y., Chen, J., and Chen, D. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology. 1995; 22: 13871392
CrossRef | PubMed

[3]Chang, M.H. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res. 2005; 11: 79537957
CrossRef | PubMed | Scopus (80)

[4]Yu, M.W., Chang, H.C., Liaw, Y.F., Lin, S.M., Lee, S.D., Liu, C.J. et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst. 2000; 92: 11591164
CrossRef | PubMed

[5]Luo, Z., Li, L., and Ruan, B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis. 2012; 16: e82e88
Abstract | Full Text | Full Text PDF | PubMed | Scopus (14)

[6]Lok, A.S.F. and McMahon, B.J. Chronic hepatitis B: update 2009. Hepatology. 2009; 50: 661662
CrossRef | PubMed | Scopus (887)

[7]Shah, U., Kelly, D., Chang, M.-H., Fujisawa, T., Heller, S., Gonzlez-Peralta, R.P. et al. Management of chronic hepatitis B in children. J Pediatr Gastroenterol Nutr. 2009; 48: 399404
CrossRef | PubMed | Scopus (27)

[8]European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012; 57: 167185
PubMed

[9]Jonas, M.M., Block, J.M., Haber, B.A., Karpen, S.J., London, W.T., Murray, K.F. et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology. 2010; 52: 21922205
CrossRef | PubMed | Scopus (32)

[10]Liang, X., Bi, S., Yang, W., Wang, L., Cui, G., Cui, F. et al. Epidemiological serosurvey of hepatitis B in Chinadeclining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009; 27: 65506557
CrossRef | PubMed | Scopus (180)

[11]Ni, Y.-H., Huang, L.M., Chang, M.-H., Yen, C.J., Lu, C.Y., You, S.-L. et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology. 2007; 132: 12871293
Abstract | Full Text | Full Text PDF | PubMed | Scopus (130)

[12]Zhang, L., Xu, A., Yan, B., Song, L., Li, M., Xiao, Z. et al. A significant reduction in hepatitis B virus infection among the children of Shandong Province, China: the effect of 15 years of universal infant hepatitis B vaccination. Int J Infect Dis. 2010; 14: e483e488
Abstract | Full Text | Full Text PDF | PubMed | Scopus (8)

[13]Liu, H.F., Sokal, E., and Goubau, P. Wide variety of genotypes and geographic origins of hepatitis B virus in Belgian children. J Pediatr Gastroenterol Nutr. 2001; 32: 274277
CrossRef | PubMed | Scopus (16)

[14]Ni, Y.-H., Chang, M.-H., Wang, K.-J., Hsu, H.-Y., Chen, H.-L., Kao, J.-H. et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology. 2004; 127: 17331738
Abstract | Full Text | Full Text PDF | PubMed | Scopus (92)

[15]Lin, C.-L. and Kao, J.-H. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol. 2011; 26: 123130
CrossRef | PubMed | Scopus (80)

[16]Zou, S., Stramer, S.L., Notari, E.P., Kuhns, M.C., Krysztof, D., Musavi, F. et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion. 2009; 49: 16091620
CrossRef | PubMed | Scopus (48)

[17]Perkins, H.A. and Busch, M.P. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion. 2010; 50: 20802099
CrossRef | PubMed | Scopus (32)

[18]Dumpis, U., Kovalova, A., Jansons, J., Upane, L., Sominskaya, I., Michailova, M. et al. An outbreak of HBV and HCV infection in a paediatric oncology ward: epidemiological investigations and prevention of further spread. J Med Virol. 2003; 69: 331338
CrossRef | PubMed | Scopus (37)

[19]McMahon, B.J., Alward, W.L., Hall, D.B., Heyward, W.L., Bender, T.R., Francis, D.P. et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985; 151: 599603
CrossRef | PubMed

[20]Tassopoulos, N.C., Papaevangelou, G.J., Sjogren, M.H., Roumeliotou-Karayannis, A., Gerin, J.L., and Purcell, R.H. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology. 1987; 92: 18441850
PubMed

[21]Beutels, P., Edmunds, W.J., Antoanzas, F., De Wit, G.A., Evans, D., Feilden, R. et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics. 2002; 20: 17
CrossRef | PubMed

[22]Kim, S.-Y., Salomon, J.A., and Goldie, S.J. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull World Health Organ. 2007; 85: 833842
PubMed

[23]Hung, H.-F. and Chen, T.H.-H. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and hepatitis B e antigen positive prevalence. Vaccine. 2009; 27: 67706776
CrossRef | PubMed | Scopus (14)

[24]Siddiqui, M.R., Gay, N., Edmunds, W.J., and Ramsay, M. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK. Vaccine. 2011; 29: 466475
CrossRef | PubMed | Scopus (7)

[25]Chen, H.-L., Lin, L.-H., Hu, F.-C., Lee, J.-T., Lin, W.-T., Yang, Y.-J. et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012; 142: e2
Abstract | Full Text PDF

[26]World Health Organization. Hepatitis B vaccines WHO position paper. Wkly Epidemiol Rec. 2009; 89: 405420

[27]Cheng, K.F., Chang, M.H., Lee, C.Y., Huang, L.M., Hsu, H.Y., Lee, P.I. et al. Response to supplementary vaccination with recombinant or plasma hepatitis B vaccine in healthy non-responding children. Vaccine. 1994; 12: 899902
CrossRef | PubMed | Scopus (22)

[28]Jafarzadeh, A., Zarei, S., and Shokri, F. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates. Vaccine. 2008; 26: 269276
CrossRef | PubMed | Scopus (17)

[29]Leonardi, S., Spina, M., Spicuzza, L., Rotolo, N., and La Rosa, M. Hepatitis B vaccination failure in celiac disease: is there a need to reassess current immunization strategies?. Vaccine. 2009; 27: 60306033
CrossRef | PubMed | Scopus (26)

[30]Vajro, P., Paolella, G., and Nobili, V. Children unresponsive to hepatitis B virus vaccination also need celiac disease testing. J Pediatr Gastroenterol Nutr. 2012; 55: e131
CrossRef | PubMed | Scopus (3)

[31]Wang, Z., Zhang, J., Yang, H., Li, X., Wen, S., Guo, Y. et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol. 2003; 71: 360366
CrossRef | PubMed | Scopus (94)

[32]McMahon, B.J., Bruden, D.L., Petersen, K.M., Bulkow, L.R., Parkinson, A.J., Nainan, O. et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005; 142: 333341
CrossRef | PubMed

[33]Mast, E.E., Margolis, H.S., Fiore, A.E., Brink, E.W., Goldstein, S.T., Wang, S.A. et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005; 54: 123
PubMed

[34]Lee, C., Gong, Y., Brok, J., Boxall, E.H., and Gluud, C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev. 2006; 2: CD004790
PubMed

[35]Iorio, R., Giannattasio, A., Cirillo, F., D Alessandro, L., and Vegnente, A. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis. 2007; 45: 943949
CrossRef | PubMed | Scopus (34)

[36]Bortolotti, F., Guido, M., Bartolacci, S., Cadrobbi, P., Crivellaro, C., Noventa, F. et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology. 2006; 43: 556562
CrossRef | PubMed | Scopus (94)

[37]Tseng, Y.-R., Wu, J.-F., Ni, Y.-H., Chen, H.-L., Chen, C.-C., Wen, W.-H. et al. Long-term effect of maternal HBeAg on delayed HBeAg seroconversion in offspring with chronic hepatitis B infection. Liver Int. 2011; 31: 13731380
CrossRef | PubMed | Scopus (7)

[38]Marx, G., Martin, S.R., Chicoine, J.-F., and Alvarez, F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis. 2002; 186: 295301
CrossRef | PubMed | Scopus (36)

[39]Wu, J.-F., Su, Y.-R., Chen, C.-H., Chen, H.-L., Ni, Y.-H., Hsu, H.-Y. et al. Predictive effect of serial serum alanine aminotransferase levels on spontaneous HBeAg seroconversion in chronic genotype B and C HBV-infected children. J Pediatr Gastroenterol Nutr. 2012; 54: 97100
CrossRef | PubMed | Scopus (3)

[40]Wen, W.-H., Chang, M.-H., Hsu, H.-Y., Ni, Y.-H., and Chen, H.-L. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr. 2004; 144: 397399
Abstract | Full Text | Full Text PDF | PubMed | Scopus (27)

[41]Chang, M.H., You, S.L., Chen, C.J., Liu, C.J., Lee, C.M., Lin, S.M. et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009; 101: 13481355
CrossRef | PubMed | Scopus (176)

[42]Iloeje, U.H., Yang, H.-I., Su, J., Jen, C.-L., You, S.-L., and Chen, C.-J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130: 678686
Abstract | Full Text | Full Text PDF | PubMed | Scopus (767)

[43]Chen, C.-J., Yang, H.-I., Su, J., Jen, C.-L., You, S.-L., Lu, S.-N. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295: 6573
CrossRef | PubMed | Scopus (1276)

[44]Yang, H.-I., Lu, S.-N., Liaw, Y.-F., You, S.-L., Sun, C.-A., Wang, L.-Y. et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002; 347: 168174
CrossRef | PubMed | Scopus (680)

[45]Kao, J.H., Chen, P.J., Lai, M.Y., and Chen, D.S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000; 118: 554559
Abstract | Full Text | Full Text PDF | PubMed

[46]Snchez-Tapias, J.M., Costa, J., Mas, A., Bruguera, M., and Rods, J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology. 2002; 123: 18481856
Abstract | Full Text | Full Text PDF | PubMed | Scopus (247)

[47]Yu, M.W., Yeh, S.H., Chen, P.J., Liaw, Y.F., Lin, C.L., Liu, C.J. et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005; 97: 265272
CrossRef | PubMed | Scopus (319)

[48]Livingston, S.E., Simonetti, J.P., McMahon, B.J., Bulkow, L.R., Hurlburt, K.J., Homan, C.E. et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis. 2007; 195: 511
CrossRef | PubMed | Scopus (106)

[49]Hsu, Y.-S., Chien, R.-N., Yeh, C.-T., Sheen, I.-S., Chiou, H.-Y., Chu, C.-M. et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002; 35: 15221527
CrossRef | PubMed | Scopus (373)

[50]Chu, C.-M. and Liaw, Y.-F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007; 45: 11871192
CrossRef | PubMed | Scopus (124)

[51]Arase, Y., Ikeda, K., Suzuki, F., Suzuki, Y., Saitoh, S., Kobayashi, M. et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med. 2006; 119: 71.e971.e16
Abstract | Full Text | Full Text PDF | Scopus (44)

[52]Chang, M.-H., Chen, P.-J., Chen, J.-Y., Lai, M.-Y., Hsu, H.-C., Lian, D.-C. et al. Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. Hepatology. 1991; 13: 316320
CrossRef | PubMed

[53]Giacchino, R., Navone, C., Facco, F., Giambartolomei, G., Pontisso, P., and Callea, F. HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases. Dig Dis Sci. 1991; 36: 11431146
CrossRef | PubMed | Scopus (15)

[54]Balshem, H., Helfand, M., Schnemann, H.J., Oxman, A.D., Kunz, R., Brozek, J. et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64: 401406
Abstract | Full Text | Full Text PDF | PubMed | Scopus (240)

[55]Guyatt, G.H., Oxman, A.D., Kunz, R., Falck-Ytter, Y., Vist, G.E., Liberati, A. et al. Going from evidence to recommendations. BMJ. 2008; 336: 10491051
CrossRef | PubMed

[56]Guyatt, G.H., Oxman, A.D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P. et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol. 2011; 64: 407415
Abstract | Full Text | Full Text PDF | PubMed | Scopus (121)

[57]Simonetti, J., Bulkow, L., McMahon, B.J., Homan, C., Snowball, M., Negus, S. et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology. 2010; 51: 15311537
CrossRef | PubMed | Scopus (56)

[58]Fattovich, G., Olivari, N., Pasino, M., DOnofrio, M., Martone, E., and Donato, F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut. 2008; 57: 8490
CrossRef | PubMed | Scopus (96)

[59]Sokal, E.M., Conjeevaram, H.S., Roberts, E.A., Alvarez, F., Bern, E.M., Goyens, P. et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology. 1998; 114: 988995
Abstract | Full Text | Full Text PDF | PubMed | Scopus (166)

[60]Jonas, M.M., Kelly, D.A., Mizerski, J., Badia, I.B., Areias, J.A., Schwarz, K.B. et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002; 346: 17061713
CrossRef | PubMed | Scopus (211)

[61]Jonas, M.M., Kelly, D., Pollack, H., Mizerski, J., Sorbel, J., Frederick, D. et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology. 2008; 47: 18631871
CrossRef | PubMed | Scopus (45)

[62]Schwimmer, J.B., Dunn, W., Norman, G.J., Pardee, P.E., Middleton, M.S., Kerkar, N. et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology. 2010; 138: 13571364
Abstract | Full Text | Full Text PDF | PubMed | Scopus (45)

[63]Hsu, E.K. and Murray, K.F. Hepatitis B and C in children. Nat Clin Pract Gastroenterol Hepatol. 2008; 5: 311320
CrossRef | PubMed | Scopus (14)

[64]Hom, X., Little, N.R., Gardner, S.D., and Jonas, M.M. Predictors of virologic response to lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J. 2004; 23: 441445
CrossRef | PubMed | Scopus (35)

[65]Katz, L.H., Fraser, A., Gafter-Gvili, A., Leibovici, L., and Tur-Kaspa, R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008; 15: 89102
PubMed

[66]Lai, C.L., Lok, A.S., Lin, H.J., Wu, P.C., Yeoh, E.K., and Yeung, C.Y. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet. 1987; 2: 877880
Abstract | PubMed

[67]Lai, C.L., Lin, H.J., Lau, J.N., Flok, A.S., Wu, P.C., Chung, H.T. et al. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med. 1991; 78: 155163
PubMed

[68]Jara, P. and Bortolotti, F. Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr. 1999; 29: 163170
CrossRef | PubMed | Scopus (77)

[69]Zoulim, F. and Locarnini, S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009; 137: 15931608
Abstract | Full Text | Full Text PDF | PubMed | Scopus (224)

[70]DAntiga, L., Aw, M., Atkins, M., Moorat, A., Vergani, D., and Mieli-Vergani, G. Combined lamivudine/interferon-alpha treatment in immunotolerant children perinatally infected with hepatitis B: a pilot study. J Pediatr. 2006; 148: 228233
Abstract | Full Text | Full Text PDF | PubMed | Scopus (47)

[71]National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Entecavir/pegylated interferon in immune tolerant children with chronic hepatitis B virus (HBV) infection. in: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000 ([cited 2012 Nov 30]. Available from: http://clinicaltrials.gov/show/NCT01368497, NLM Identifier: NCT01368497)
http://clinicaltrials.gov/show/NCT01368497 | NCT01368497

[72]Roche. Lamivudine/pegylated interferon in immune tolerant children with chronic hepatitis B virus infection. Single center clinical trial at the Paediatric Liver Centre, Kings College Hospital, London, United Kingdom. Study identifier: NV2536.

[73]Bortolotti, F., Jara, P., Barbera, C., Gregorio, G.V., Vegnente, A., Zancan, L. et al. Long term effect of alpha interferon in children with chronic hepatitis B. Gut. 2000; 46: 715718
CrossRef | PubMed | Scopus (97)

[74]Vo Thi Diem, H., Bourgois, A., Bontems, P., Goyens, P., Buts, J.-P., Nackers, F. et al. Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls. J Pediatr Gastroenterol Nutr. 2005; 40: 141145
CrossRef | PubMed | Scopus (25)

[75]Sokal, E.M., Kelly, D.A., Mizerski, J., Badia, I.B., Areias, J.A., Schwarz, K.B. et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology. 2006; 43: 225232
CrossRef | PubMed | Scopus (72)

[76]Schalm, S.W., Heathcote, J., Cianciara, J., Farrell, G., Sherman, M., Willems, B. et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 2000; 46: 562568
CrossRef | PubMed | Scopus (465)

[77]Sarin, S.K., Kumar, M., Kumar, R., Kazim, S.N., Guptan, R.C., Sakhuja, P. et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol. 2005; 100: 24632471
CrossRef | PubMed | Scopus (33)

[78]Dikici, B., Bosnak, M., Bosnak, V., Dagli, A., Ece, A., Yagci, R.V. et al. Combination therapy for children with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2002; 17: 10871091
CrossRef | PubMed | Scopus (30)

[79]Yilmaz, A., Akcam, M., Gelen, T., and Artan, R. Lamivudine and high-dose interferon alpha 2a combination treatment in nave HBeAg-positive immunoactive chronic hepatitis B in children: an East Mediterranean centers experience. Eur J Pediatr. 2006; 166: 195199
CrossRef | PubMed | Scopus (13)

[80]Akman, S.A., Okcu, S.C., Halicioglu, O., Sutcuoglu, S., Anil, M., Kizilgunesler, A. et al. Therapeutic efficacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B. Pediatr Int. 2007; 49: 848852
CrossRef | PubMed | Scopus (11)

[81]Jonas, M.M., Kelly, D., Pollack, H., Mizerski, J., Sorbel, J., Frederick, D. et al. Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. Pediatr Infect Dis J. 2012; 31: 578582
CrossRef | PubMed | Scopus (6)

[82]Marcellin, P., Chang, T.-T., Lim, S.G.L., Sievert, W., Tong, M., Arterburn, S. et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008; 48: 750758
CrossRef | PubMed | Scopus (161)

[83]Chang, T.-T., Gish, R.G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C. et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354: 10011010
CrossRef | PubMed | Scopus (793)

[84]Sherman, M., Yurdaydin, C., Simsek, H., Silva, M., Liaw, Y.-F., Rustgi, V.K. et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008; 48: 99108
CrossRef | PubMed | Scopus (100)

[85]Marcellin, P., Heathcote, E.J., Buti, M., Gane, E., de Man, R.A., Krastev, Z. et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359: 24422455
CrossRef | PubMed | Scopus (453)

[86]Murray, K.F., Szenborn, L., Wysocki, J., Rossi, S., Corsa, A.C., Dinh, P. et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology. 2012; 56: 20182026
CrossRef | PubMed | Scopus (10)

[87]Lau, G.K.K., Piratvisuth, T., Luo, K.X., Marcellin, P., Thongsawat, S., Cooksley, G. et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352: 26822695
CrossRef | PubMed | Scopus (832)

[88]Janssen, H.L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U.S., Cakaloglu, Y. et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005; 365: 123129
Abstract | Full Text | Full Text PDF | PubMed | Scopus (633)

[89]Hoffmann-La Roche. A study of pegasys (peginterferon Alfa-2a) versus untreated control in children with HBeAg positive chronic hepatitis B. in: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000 ([cited 2012 Nov 30]. Available from: http://clinicaltrials.gov/show/NCT01519960, NLM Identifier: NCT01519960)
http://clinicaltrials.gov/show/NCT01519960 | NCT01519960

[90]Liaw, Y.F., Gane, E., Leung, N., Zeuzem, S., Wang, Y., Lai, C.L. et al. 2-Year globe trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009; 136: 486495
Abstract | Full Text | Full Text PDF | PubMed | Scopus (274)

[91]Kobak, G.E., MacKenzie, T., Sokol, R.J., and Narkewicz, M.R. Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger. J Pediatr. 2004; 145: 340345
Abstract | Full Text | Full Text PDF | PubMed | Scopus (26)

[92]Perrillo, R.P., Schiff, E.R., Davis, G.L., Bodenheimer, H.C., Lindsay, K., Payne, J. et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990; 323: 295301
CrossRef | PubMed

[93]Wong, D., Cheung, A., ORourke, K., Naylor, C., Detsky, A., and Heathcote, J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119: 312323
CrossRef | PubMed

[94]Wai, C.T., Chu, C.-J., Hussain, M., and Lok, A.S.F. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology. 2002; 36: 14251430
CrossRef | PubMed

[95]Erhardt, A. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut. 2005; 54: 10091013
CrossRef | PubMed | Scopus (145)

[96]Flink, H.J., van Zonneveld, M., Hansen, B.E., de Man, R.A., Schalm, S.W., Janssen, H.L.A. et al. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006; 101: 297303
CrossRef | PubMed | Scopus (156)

[97]Brunetto, M.R., Moriconi, F., Bonino, F., Lau, G.K.K., Farci, P., Yurdaydin, C. et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009; 49: 11411150
CrossRef | PubMed | Scopus (240)

[98]Moucari, R., Mackiewicz, V., Lada, O., Ripault, M.-P., Castelnau, C., Martinot-Peignoux, M. et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009; 49: 11511157
CrossRef | PubMed | Scopus (227)

[99]Moucari, R., Martinot-Peignoux, M., Mackiewicz, V., Boyer, N., Ripault, M.P., Castelnau, C. et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther. 2009; 14: 11831188
CrossRef | PubMed | Scopus (42)

[100]Perrillo, R. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002; 36: 186194
CrossRef | PubMed | Scopus (236)

[101]Marcellin, P., Chang, T.-T., Lim, S.-G., Tong, M.J., Sievert, W., Shiffman, M.L. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003; 348: 808816
CrossRef | PubMed | Scopus (1013)

[102]Wiegand, J., Hasenclever, D., and Tillmann, H.L. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther. 2008; 13: 211220
PubMed

[103]Raimondi, S., Maisonneuve, P., Bruno, S., and Mondelli, M.U. Is response to antiviral treatment influenced by hepatitis B virus genotype?. J Hepatol. 2010; 52: 441449
Abstract | Full Text | Full Text PDF | PubMed | Scopus (27)

[104]Yuen, M. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001; 34: 785791
CrossRef | PubMed | Scopus (305)

[105]Zeuzem, S., Gane, E., Liaw, Y.F., Lim, S.G., DiBisceglie, A., Buti, M. et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 2009; 51: 1120
Abstract | Full Text | Full Text PDF | PubMed | Scopus (104)

[106]Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.-T., Kitis, G., Rizzetto, M. et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131: 17431751
Abstract | Full Text | Full Text PDF | PubMed | Scopus (531)

[107]Wursthorn, K., Jung, M., Riva, A., Goodman, Z.D., Lopez, P., Bao, W. et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010; 52: 16111620
CrossRef | PubMed | Scopus (83)

[108]Lee, J.M., Ahn, S.H., Kim, H.S., Park, H., Chang, H.Y., Kim, D.Y. et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology. 2011; 53: 14861493
CrossRef | PubMed | Scopus (46)

[109]Chan, H.L.-Y., Thompson, A., Martinot-Peignoux, M., Piratvisuth, T., Cornberg, M., Brunetto, M.R. et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 a core group report. J Hepatol. 2011; 55: 11211131
Abstract | Full Text | Full Text PDF | PubMed | Scopus (83)

[110]Boxall, E.H., Sira, J., Ballard, A.L., Davies, P., and Kelly, D.A. Long-term follow-up of hepatitis B carrier children treated with interferon and prednisolone. J Med Virol. 2006; 78: 888895
CrossRef | PubMed | Scopus (15)

[111]Gregorio, G.V., Jara, P., Hierro, L., Diaz, C., Vega, La. et al. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology. 1996; 23: 700707
CrossRef | PubMed

[112]Vajro, P., Tedesco, M., Fontanella, A., De Vincenzo, A., Vecchione, R., Ammendola, R. et al. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J. 1996; 15: 223231
CrossRef | PubMed | Scopus (35)

[113]Dubois, J., Hershon, L., Carmant, L., Blanger, S., Leclerc, J.M., and David, M. Toxicity profile of interferon alfa-2b in children: a prospective evaluation. J Pediatr. 1999; 135: 782785
Abstract | Full Text | Full Text PDF | PubMed

[114]Sokal, E.M., Roberts, E.A., Mieli-Vergani, G., McPhillips, P., Johnson, M., Barber, J. et al. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother. 2000; 44: 590597
CrossRef | PubMed | Scopus (54)

[115]Jonas, M.M., Little, N.R., and Gardner, S.D. International Pediatric Lamivudine Investigator Group. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety. J Viral Hepat. 2008; 15: 2027
PubMed

[116]Papatheodoridis, G.V., Manesis, E.K., and Hadziyannis, S.J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001; 34: 306313
Abstract | Full Text | Full Text PDF | PubMed | Scopus (236)

[117]Santantonio, T., Mazzola, M., Iacovazzi, T., Miglietta, A., Guastadisegni, A., and Pastore, G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol. 2000; 32: 300306
Abstract | Full Text | Full Text PDF | PubMed | Scopus (231)

[118]Hadziyannis, S.J., Sevastianos, V., Rapti, I., Vassilopoulos, D., and Hadziyannis, E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology. 2012; 143: 629636
Abstract | Full Text | Full Text PDF | PubMed | Scopus (16)

[119]Chang, T.-T., Gish, R.G., Hadziyannis, S.J., Cianciara, J., Rizzetto, M., Schiff, E.R. et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005; 129: 11981209
Abstract | Full Text | Full Text PDF | PubMed | Scopus (197)

[120]Shapira, R., Mor, E., Bar-Nathan, N., Sokal, E.M., Tur-Kaspa, R., Dinari, G. et al. Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children. Transplantation. 2001; 72: 333336
CrossRef | PubMed

[121]Natov, S.N. and Pereira, B.J.G. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (Part 1: hepatitis B virus). Transpl Infect Dis. 2002; 4: 117123
CrossRef | PubMed | Scopus (31)

[122]Dickson, R.C., Everhart, J.E., Lake, J.R., Wei, Y., Seaberg, E.C., Wiesner, R.H. et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology. 1997; 113: 16681674
Abstract | Full Text | Full Text PDF | PubMed | Scopus (309)

[123]Wachs, M.E., Amend, W.J., Ascher, N.L., Bretan, P.N., Emond, J., Lake, J.R. et al. The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation. 1995; 59: 230234
CrossRef | PubMed

[124]Cholongitas, E., Papatheodoridis, G.V., and Burroughs, A.K. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol. 2010; 52: 272279
Abstract | Full Text | Full Text PDF | PubMed | Scopus (66)

[125]Su, W.-J., Ho, M.-C., Ni, Y.-H., Chen, H.-L., Hu, R.-H., Wu, Y.-M. et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr. 2009; 48: 203208
CrossRef | PubMed | Scopus (19)

[126]Perrillo, R. and Hepatitis, B. Virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl. 2009; 15: 223232
CrossRef | PubMed | Scopus (34)

[127]Thio, C.L., Seaberg, E.C., Skolasky, R.J., Phair, J., Visscher, B., Munoz, A. et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002; 360: 19211926
Abstract | Full Text | Full Text PDF | PubMed | Scopus (541)

[128]Benhamou, Y., Bochet, M., Thibault, V., Di Martino, V., Caumes, E., Bricaire, F. et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999; 30: 13021306
CrossRef | PubMed | Scopus (308)

[129]McMahon, M.A., Jilek, B.L., Brennan, T.P., Shen, L., Zhou, Y., Wind-Rotolo, M. et al. The HBV drug entecavir effects on HIV-1 replication and resistance. N Engl J Med. 2007; 356: 26142621
CrossRef | PubMed | Scopus (159)

[130]Soriano, V., Puoti, M., Bonacini, M., Brook, G., Cargnel, A., Rockstroh, J. et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS. 2005; 19: 221240
CrossRef | PubMed

[131]Mofenson, L.M., Brady, M.T., Danner, S.P., Dominguez, K.L., Hazra, R., Handelsman, E. et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009; 58: 1166
PubMed

[132]Di Marco, V., Giacchino, R., Timitilli, A., Bortolotti, F., Crivellaro, C., Calzia, R. et al. Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study. J Viral Hepat. 1996; 3: 123128
CrossRef | PubMed

[133]Rizzetto, M. Hepatitis D: thirty years after. J Hepatol. 2009; 50: 10431050
Abstract | Full Text | Full Text PDF | PubMed | Scopus (84)

[134]Brown, R.S. Jr., Verna, E.C., Pereira, M.R., Tilson, H.H., Aguilar, C., Leu, C.-S. et al. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol. 2012; 57: 953959
Abstract | Full Text | Full Text PDF | PubMed | Scopus (7)

[135]Xu, W.M., Cui, Y.T., Wang, L., Yang, H., Liang, Z.Q., Li, X.M. et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009; 16: 94103
CrossRef | PubMed | Scopus (120)

[136]Shi, Z., Yang, Y., Ma, L., Li, X., and Schreiber, A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010; 116: 147159
CrossRef | PubMed | Scopus (56)

[137]Han, G.-R., Cao, M.-K., Zhao, W., Jiang, H.-X., Wang, C.-M., Bai, S.-F. et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011; 55: 12151221
Abstract | Full Text | Full Text PDF | PubMed | Scopus (56)

[138]Weinbaum, C.M., Williams, I., Mast, E.E., Wang, S.A., Finelli, L., Wasley, A. et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008; 57: 120
PubMed

[139]Sokal, E.M., Van Collie, O., and Buts, J.P. Horizontal transmission of hepatitis B from children to adoptive parents. Arch Dis Child. 1995; 72: 191
CrossRef | PubMed

[140]Martin, A., Moyes, C., Lucas, C., and Milne, A. Hepatitis B infection in households of HBsAg positive New Zealand children. N Z Med J. 1996; 109: 463465
PubMed

[141]Staff, M. and Angel, P. Vaccination among household contacts of chronic hepatitis B carriers by general practitioners. Aust Fam Physician. 2002; 31: 491493
PubMed

[142]Chakravarty, R., Chowdhury, A., Chaudhuri, S., Santra, A., Neogi, M., Rajendran, K. et al. Hepatitis B infection in Eastern Indian families: need for screening of adult siblings and mothers of adult index cases. Public Health. 2005; 119: 647654
Abstract | Full Text | Full Text PDF | PubMed | Scopus (20)

[143]Kumar, G.T., Kazim, S.N., Kumar, M., Hissar, S., Chauhan, R., Basir, S.F. et al. Hepatitis B virus genotypes and hepatitis B surface antigen mutations in family contacts of hepatitis B virus infected patients with occult hepatitis B virus infection. J Gastroenterol Hepatol. 2009; 24: 588598
CrossRef | PubMed | Scopus (8)

[144]Richardson, G., Evans, M.R., and Westmoreland, D. Hepatitis B immunisation of household contacts: retrospective study of vaccine coverage. J Epidemiol Community Health. 2001; 55: 934935
CrossRef | PubMed | Scopus (6)

[145]Weinberg, M.S., Gunn, R.A., Mast, E.E., Gresham, L., and Ginsberg, M. Preventing transmission of hepatitis B virus from people with chronic infection. Am J Prev Med. 2001; 20: 272276
Abstract | Full Text | Full Text PDF | PubMed | Scopus (14)

[146]Scognamiglio, P., Girardi, E., Fusco, M., Piselli, P., Russo Spena, S., Maione, C. et al. Lack of implementation of hepatitis B virus (HBV) vaccination policy in household contacts of HBV carriers in Italy. BMC Infect Dis. 2009; 9: 86
CrossRef | PubMed | Scopus (3)

[147]Losonsky, G.A., Wasserman, S.S., Stephens, I., Mahoney, F., Armstrong, P., Gumpper, K. et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics. 1999; 103: E14
CrossRef | PubMed

[148]European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet. 2000; 355: 561565
Abstract | Full Text | Full Text PDF | PubMed

[149]Lu, C.Y., Ni, Y.H., Chiang, B.L., Chen, P.J., Chang, M.H., Chang, L.Y. et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 1518 years after neonatal immunization. J Infect Dis. 2008; 197: 14191426
CrossRef | PubMed | Scopus (66)

[150]van der Sande, M.A., Waight, P., Mendy, M., Rayco-Solon, P., Hutt, P., Fulford, T. et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis. 2006; 193: 15281535
CrossRef | PubMed | Scopus (61)

[151]Whitaker, J.A., Rouphael, N.G., Edupuganti, S., Lai, L., and Mulligan, M.J. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis. 2012; 12: 966976
Abstract | Full Text | Full Text PDF | PubMed | Scopus (3)

[152]Yang, J., Zeng, X.M., Men, Y.L., and Zhao, L.S. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus a systematic review. Virol J. 2008; 5: 100
CrossRef | PubMed | Scopus (36)

[153]Shi, Z., Yang, Y., Wang, H., Ma, L., Schreiber, A., Li, X. et al. Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. Arch Pediatr Adolesc Med. 2011; 165: 837846
CrossRef | PubMed | Scopus (22)

[154]World Health Organization. Hepatitis B and breastfeeding. World Health Organization. J Int Assoc Physicians AIDS Care. 1998; 4: 2021

[155]Moodley, J., Moodley, D., Pillay, K., Coovadia, H., Saba, J., van Leeuwen, R. et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998; 178: 13271333
CrossRef | PubMed | Scopus (132)

[156]Giles, M., Visvanathan, K., and Sasadeusz, J. Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding. Antivir Ther. 2011; 16: 621628
CrossRef | PubMed | Scopus (10)

[157]Wen, W.H., Chen, H.L., Ni, Y.H., Hsu, H.Y., Kao, J.H., and Hu, F.C. Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Hepatology. 2011; 53: 429436
CrossRef | PubMed | Scopus (15)

[158]Milich, D.R., Jones, J.E., Hughes, J.L., Price, J., Raney, A.K., and McLachlan, A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?. Proc Natl Acad Sci U S A. 1990; 87: 65996603
CrossRef | PubMed

[159]Chen, M.T., Billaud, J.N., Sllberg, M., Guidotti, L.G., Chisari, F.V., Jones, J. et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci U S A. 2004; 101: 1491314918
CrossRef | PubMed | Scopus (96)

[160]Milich, D. and Liang, T.J. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology. 2003; 38: 10751086
CrossRef | PubMed | Scopus (151)

[161]Jang, J.W., Yoo, S.H., Kwon, J.H., You, C.R., Lee, S., Lee, J.H. et al. Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection. Aliment Pharmacol Ther. 2011; 34: 13371346
CrossRef | PubMed | Scopus (5)

[162]Marcellin, P., Ziol, M., Bedossa, P., Douvin, C., Poupon, R., de Ldinghen, V. et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009; 29: 242247
CrossRef | PubMed | Scopus (185)

[163]Castera, L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat. 2009; 16: 300314
CrossRef | PubMed | Scopus (76)

[164]Cardoso, A.C., Carvalho-Filho, R.J., Stern, C., Dipumpo, A., Giuily, N., Ripault, M.P. et al. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int. 2012; 32: 612621
CrossRef | PubMed | Scopus (23)

[165]Poynard, T., Munteanu, M., Deckmyn, O., Ngo, Y., Drane, F., and Castille, J.M. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol. 2012; 57: 541548
Abstract | Full Text | Full Text PDF | PubMed | Scopus (9)

[166]Liaw, Y.F., Jia, J.D., Chan, H.L., Han, K.H., Tanwandee, T., Chuang, W.L. et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011; 54: 15911599
CrossRef | PubMed | Scopus (39)

[167]Marcellin, P., Lau, G.K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R. et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351: 12061217
CrossRef | PubMed | Scopus (719)

[168]Fleischer, R.D. and Lok, A.S. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol. 2009; 51: 787791
Abstract | Full Text | Full Text PDF | PubMed | Scopus (41)

[169]Lee, H.W., Lee, H.J., Hwang, J.S., Sohn, J.H., Jang, J.Y., Han, K.J. et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology. 2010; 51: 415421
CrossRef | PubMed | Scopus (32)

[170]Reijnders, J.G., Perquin, M.J., Zhang, N., Hansen, B.E., and Janssen, H.L. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology. 2010; 139: 491498
Abstract | Full Text | Full Text PDF | PubMed | Scopus (61)

[171]Petersen, J., Ratziu, V., Buti, M., Janssen, H.L., Brown, A., Lampertico, P. et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol. 2012; 56: 520526
Abstract | Full Text | Full Text PDF | PubMed | Scopus (31)

[172]Liaw, Y.F., Sheen, I.S., Lee, C.M., Akarca, U.S., Papatheodoridis, G.V., Suet-Hing Wong, F. et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011; 53: 6272
CrossRef | PubMed | Scopus (106)

[173]Gordon, S.C., Krastev, Z., Horban, A., Petersen, J., Sperl, J., Dinh, P. et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis b with high baseline viral load (⩾9 log10 copies/mL). Hepatology. 2013; DOI: http://dx.doi.org/10.1002/hep.26277 ([Epub ahead of print])
http://dx.doi.org/10.1002/hep.26277 | CrossRef | Scopus (6)

[174]Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I.M. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013; 381: 468475
Abstract | Full Text | Full Text PDF | PubMed | Scopus (75)

[175]Chang, T.T., Lai, C.L., Kew Yoon, S., Lee, S.S., Coelho, H.S., Carrilho, F.J. et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010; 51: 422430
CrossRef | PubMed | Scopus (159)

[176]Chang, T.T., Liaw, Y.F., Wu, S.S., Schiff, E., Han, K.H., Lai, C.L. et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010; 52: 886893
CrossRef | PubMed | Scopus (177)

[177]Marzano, A., Angelucci, E., Andreone, P., Brunetto, M., Bruno, R., Burra, P. et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007; 39: 397408
Abstract | Full Text | Full Text PDF | PubMed | Scopus (126)

[178]Loomba, R., Rowley, A., Wesley, R., Liang, T.J., Hoofnagle, J.H., Pucino, F. et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008; 148: 519528
CrossRef | PubMed

[179]Hsu, C., Hsiung, C.A., Su, I.J., Hwang, W.S., Wang, M.C., Lin, S.F. et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkins lymphoma: a randomized trial. Hepatology. 2008; 47: 844853
CrossRef | PubMed | Scopus (118)

[180]Evens, A.M., Jovanovic, B.D., Su, Y.C., Raisch, D.W., Ganger, D., Belknap, S.M. et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011; 22: 11701180
CrossRef | PubMed | Scopus (58)

[181]Vigan, M., Vener, C., Lampertico, P., Annaloro, C., Pichoud, C., Zoulim, F. et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011; 46: 125131
CrossRef | PubMed | Scopus (20)

[182]HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines, section accessed February 21st 2013.
http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines

[183]Shiraki, K., Yoshihara, N., Sakurai, M., Eto, T., and Kawana, T. Acute hepatitis B in infants born to carrier mother with the antibody to hepatitis B e antigen. J Pediatr. 1980; 97: 768770
Abstract | Full Text PDF | PubMed

[184]Bortolotti, F., Cadrobbi, P., Bertaggia, A., Rude, L., Alberti, A., and Realdi, G. A 7 year survey of acute hepatitis type B. Arch Dis Child. 1983; 58: 993996
CrossRef | PubMed

[185]Squires, R.H. Jr., Shneider, B.L., Bucuvalas, J., Alonso, E., Sokol, R.J., Narkewicz, M.R. et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr. 2006; 148: 652658
Abstract | Full Text | Full Text PDF | PubMed | Scopus (174)

[186]Sundaram, S.S., Alonso, E.M., Narkewicz, M.R., Zhang, S., and Squires, R.H. Pediatric Acute Liver Failure Study Group. Characterization and outcomes of young infants with acute liver failure. J Pediatr. 2011; 159: 813818
Abstract | Full Text | Full Text PDF | PubMed | Scopus (13)

[187]Tillmann, H.L., Hadem, J., Leifeld, L., Zachou, K., Canbay, A., Eisenbach, C. et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006; 13: 256263
CrossRef | PubMed | Scopus (112)

[188]Dienstag, J.L., Schiff, E.R., Wright, T.L., Perrillo, R.P., Hann, H.L., Goodman, Z. et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999; 341: 12561263
CrossRef | PubMed | Scopus (1161)

[189]Gilead Sciences. Evaluating the efficacy, safety and tolerability of tenofovir DF in pediatric patients with chronic hepatitis B infection. in: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000 ([cited 2013 May 5]. Available from: http://clinicaltrials.gov/show/NCT01651403, ClinicalTrials.gov Identifier: NCT01651403)
http://clinicaltrials.gov/show/NCT01651403 | NCT01651403

[190]Bruix, J. and Sherman, M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 10201022
CrossRef | PubMed | Scopus (961)

[191]Singal, A., Volk, M.L., Waljee, A., Salgia, R., Higgins, P., Rogers, M.A. et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009; 30: 3747
CrossRef | PubMed | Scopus (104)

[192]Lok, A.S., Sterling, R.K., Everhart, J.E., Wright, E.C., Hoefs, J.C., Di Bisceglie, A.M. et al. HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010; 138: 493502
Abstract | Full Text | Full Text PDF | PubMed | Scopus (98)